Astec Lifesciences' Q1 FY 2026-27 Quarterly Results
- 01 Aug 2026
Result Summary
- Astec Lifesciences Ltd reported a 47.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 8.0%.
- Its expenses for the quarter were down by 39.1% QoQ and 17.3% YoY.
- The net profit increased 141.4% QoQ and decreased 43.4% YoY.
- The earnings per share (EPS) of Astec Lifesciences Ltd declined at 8.4 during Q1 FY 2026-27.
Financial Statments for Q1 FY 2026-27
(₹ crores) | Q1FY27 | Q4FY26 | Q1FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 84.29 | 161.26 | 91.59 | -47.7% | -8.0% |
Total Expenses | 103.03 | 169.15 | 124.60 | -39.1% | -17.3% |
Profit Before Tax | -18.74 | -7.90 | -33.02 | 137.2% | -43.2% |
Tax | -0.03 | -0.15 | 0.01 | -80.0% | -400.0% |
Profit After Tax | -18.71 | -7.75 | -33.03 | 141.4% | -43.4% |
Earnings Per Share | -8.40 | -3.48 | -16.85 | 141.4% | -50.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Astec Lifesciences Ltd is a company operating in the chemical sector, specializing in the production and sale of agrochemical active ingredients and intermediates. The company primarily focuses on manufacturing a wide range of crop protection products, which are crucial for agricultural productivity. These products include fungicides, herbicides, and insecticides. Astec Lifesciences Ltd is committed to research and development in order to innovate and improve its product offerings. As of the most recent updates, there are no major developments or changes in the company’s operations or strategic direction that are publicly available.
Revenue
In the first quarter of fiscal year 2027 (Q1FY27), Astec Lifesciences Ltd reported a total income of ₹84.29 crores. When compared to the previous quarter (Q4FY26), the total income decreased by 47.7% from ₹161.26 crores. This represents a significant quarter-over-quarter decline in revenue. Comparing year-over-year figures, the total income also saw a decrease of 8.0% from ₹91.59 crores in Q1FY26. These changes reflect the revenue trajectory of the company over the periods under consideration.
Profitability
Astec Lifesciences Ltd's profitability for Q1FY27 shows a profit before tax (PBT) of -₹18.74 crores. This represents an increase of 137.2% from the previous quarter's PBT of -₹7.90 crores. However, when compared to Q1FY26's PBT of -₹33.02 crores, there is a decrease of 43.2%. The profit after tax (PAT) for Q1FY27 is reported as -₹18.71 crores, marking an increase of 141.4% from the previous quarter's PAT of -₹7.75 crores. Year-over-year, this reflects a decrease of 43.4% from a PAT of -₹33.03 crores in Q1FY26. The earnings per share (EPS) is recorded at -₹8.40 for Q1FY27, which is a significant increase from the previous quarter's EPS of -₹3.48 and shows a decrease from the -₹16.85 reported in Q1FY26.
Operating Metrics
Astec Lifesciences Ltd's total expenses for Q1FY27 were reported at ₹103.03 crores, showing a reduction of 39.1% from the ₹169.15 crores in Q4FY26. Comparing year-over-year, the total expenses have decreased by 17.3% from ₹124.60 crores in Q1FY26. The tax component for Q1FY27 was -₹0.03 crores, indicating a decrease of 80.0% from the previous quarter's tax of -₹0.15 crores. Year-over-year, there is a significant change from the Q1FY26 tax figure of ₹0.01 crores, reflecting a 400.0% decrease. These metrics provide insights into the company’s cost management and operational efficiency over the periods analyzed.
FAQs
Astec Lifesciences Ltd announced its Q1 FY 2026-27 results on 1 August, 2026.
Astec Lifesciences Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Astec Lifesciences Ltd Q1 FY 2026-27 results include:
- Revenue: ₹84.29 crore
- Net Profit: ₹-18.71 crore
- EBITDA: ₹0.06 crore
- Year-over-Year Growth: -8.0%
- Quarter-over-Quarter Growth: -47.7%
Astec Lifesciences Ltd reported a net profit of ₹-18.71 crore in Q1 FY 2026-27, reflecting a -43.4% year-over-year growth.
Astec Lifesciences Ltd posted a revenue of ₹84.29 crore in Q1 FY 2026-27.